KR101478133B1 - 1-（치환된 벤질기）-5-트리플루오로메틸-2-（1ｈ）피리돈 화합물 및 그 염의 제조방법 및 용도 - Google Patents

1-（치환된 벤질기）-5-트리플루오로메틸-2-（1ｈ）피리돈 화합물 및 그 염의 제조방법 및 용도 Download PDF

Info

Publication number
KR101478133B1
KR101478133B1 KR1020117030958A KR20117030958A KR101478133B1 KR 101478133 B1 KR101478133 B1 KR 101478133B1 KR 1020117030958 A KR1020117030958 A KR 1020117030958A KR 20117030958 A KR20117030958 A KR 20117030958A KR 101478133 B1 KR101478133 B1 KR 101478133B1
Authority
KR
South Korea
Prior art keywords
trifluoromethyl
pyridone
group
benzyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117030958A
Other languages
English (en)
Korean (ko)
Other versions
KR20120060785A (ko
Inventor
가오윤 후
리지안 타오
준 첸
Original Assignee
센트럴 사우스 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 센트럴 사우스 유니버시티 filed Critical 센트럴 사우스 유니버시티
Publication of KR20120060785A publication Critical patent/KR20120060785A/ko
Application granted granted Critical
Publication of KR101478133B1 publication Critical patent/KR101478133B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020117030958A 2009-05-25 2010-05-24 1-（치환된 벤질기）-5-트리플루오로메틸-2-（1ｈ）피리돈 화합물 및 그 염의 제조방법 및 용도 Expired - Fee Related KR101478133B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200910043502.1 2009-05-25
CN200910043502 2009-05-25
PCT/CN2010/073131 WO2010135976A1 (zh) 2009-05-25 2010-05-24 1-（取代苄基）-5-三氟甲基-2-（1h）吡啶酮化合物及其盐，其制备方法及其用途

Publications (2)

Publication Number Publication Date
KR20120060785A KR20120060785A (ko) 2012-06-12
KR101478133B1 true KR101478133B1 (ko) 2014-12-31

Family

ID=43222161

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117030958A Expired - Fee Related KR101478133B1 (ko) 2009-05-25 2010-05-24 1-（치환된 벤질기）-5-트리플루오로메틸-2-（1ｈ）피리돈 화합물 및 그 염의 제조방법 및 용도

Country Status (9)

Country Link
US (1) US8377932B2 (https=)
EP (1) EP2474533B1 (https=)
JP (1) JP5722883B2 (https=)
KR (1) KR101478133B1 (https=)
CN (1) CN102149683B (https=)
AU (1) AU2010252451B2 (https=)
DK (1) DK2474533T3 (https=)
ES (1) ES2536200T3 (https=)
WO (1) WO2010135976A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
JP5924984B2 (ja) * 2012-03-06 2016-05-25 国立大学法人東京農工大学 トリフルオロメチルピリジノン化合物およびその製造方法
BR112014030284B1 (pt) 2012-07-18 2021-11-30 Sunshine Lake Pharma Co., Ltd Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
KR20150018127A (ko) * 2013-08-09 2015-02-23 삼성전자주식회사 디스플레이 장치 및 그 방법
US9902712B2 (en) 2013-12-19 2018-02-27 Sunshine Lake Pharma Co., Ltd. Nitrogenous heterocyclic derivatives and their application in drugs
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
CN106466318B (zh) * 2015-08-21 2019-01-01 中南大学 1-杂环取代苄基吡啶酮类化合物在制备治疗糖尿病肾病药物中的应用
CN107663167A (zh) * 2016-10-19 2018-02-06 广州南新制药有限公司 1‑（取代苄基）‑5‑三氟甲基‑2(1h)‑吡啶酮盐酸盐的晶型及制备方法
CN107652228B (zh) * 2016-10-28 2020-04-14 广州南新制药有限公司 抗肾纤维化药物1-（取代苄基）-5-三氟甲基-2(1h)-吡啶酮盐酸盐的合成方法
CN113456642B (zh) * 2021-07-09 2022-09-06 中南大学 一种美氟尼酮在制备治疗急性肾损伤药物中的应用
WO2023168649A1 (zh) * 2022-03-10 2023-09-14 广州南新制药有限公司 一种美氟尼酮盐酸盐的制备方法
WO2023168650A1 (zh) * 2022-03-10 2023-09-14 广州南新制药有限公司 一种美氟尼酮晶型的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009392A2 (en) * 2003-07-23 2005-02-03 Bristol-Myers Squibb Company Dihydropyrimidone inhibitors of calcium channel function

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839346A (en) 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
US4052509A (en) 1972-12-18 1977-10-04 Affiliated Medical Research, Inc. Method for reducing serum uric acid levels
US4042699A (en) 1972-12-18 1977-08-16 Affiliated Medical Research, Inc. Method for reducing serum glucose levels
GB8523126D0 (en) * 1985-09-19 1985-10-23 Ici Plc Aryl pyridones
GB8621217D0 (en) 1986-09-03 1986-10-08 Ici Plc Chemical compounds
GB8825314D0 (en) 1988-10-28 1988-11-30 Ici Plc Chemical compounds
GB9006479D0 (en) 1989-04-17 1990-05-23 Ici Plc Novel compounds
US5310562A (en) 1989-11-22 1994-05-10 Margolin Solomon B Composition and method for reparation and prevention of fibrotic lesions
US5518729A (en) 1989-11-22 1996-05-21 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5716632A (en) 1989-11-22 1998-02-10 Margolin; Solomon B. Compositions and methods for reparation and prevention of fibrotic lesions
US5238906A (en) 1990-11-27 1993-08-24 Sumitomo Chemical Company, Limited Pyridone derivatives and use
DE4343528A1 (de) 1993-12-16 1995-06-22 Schering Ag Zweifach heterocyclisch substituierte Benzole und Pyridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Schädlingsbekämpfungsmittel
ATE448784T1 (de) * 2002-02-14 2009-12-15 Pharmacia Corp Substituierte pyridinone als modulatoren für p38 map kinase
CN1218942C (zh) * 2002-06-11 2005-09-14 中南大学湘雅医学院 抗纤维化吡啶酮化合物及其生产工艺方法
GB0324159D0 (en) * 2003-10-15 2003-11-19 Glaxo Group Ltd Novel compounds
CN100358872C (zh) 2003-11-14 2008-01-02 上海睿星基因技术有限公司 吡啶酮衍生物及其应用
DE102004027359A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyridin-2-onverbindungen und deren Verwendung
ES2600460T3 (es) 2005-05-10 2017-02-09 Intermune, Inc. Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés
CN101237869A (zh) * 2005-05-10 2008-08-06 英特芒尼公司 用于调节应激-活化蛋白激酶系统的吡啶酮衍生物
WO2007053610A2 (en) 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
KR20080076968A (ko) 2005-11-23 2008-08-20 인터뮨, 인크. 스트레스-활성화 단백질 키나제 시스템을 조절하는 방법
CN101235030A (zh) * 2007-01-30 2008-08-06 中南大学 1-取代-5-三氟甲基-2-(1h)吡啶酮化合物、制备方法及其用途
US20090118135A1 (en) 2007-06-08 2009-05-07 The Burnham Institute Methods and compounds for regulating apoptosis
CN101371833A (zh) 2007-08-23 2009-02-25 中南大学 1-芳基-2(1h)-吡啶酮类化合物在制备治疗皮肤瘙痒药物中的应用
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
AP2011005824A0 (en) 2009-01-26 2011-08-31 Intermune Inc Methods for treating acute myocardial infarctions and associated disorders.
WO2010135470A1 (en) 2009-05-19 2010-11-25 Intermune, Inc. Pifenidone derivatives for treating bronchial asthma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005009392A2 (en) * 2003-07-23 2005-02-03 Bristol-Myers Squibb Company Dihydropyrimidone inhibitors of calcium channel function

Also Published As

Publication number Publication date
AU2010252451B2 (en) 2014-04-03
CN102149683A (zh) 2011-08-10
AU2010252451A1 (en) 2011-12-15
ES2536200T3 (es) 2015-05-21
KR20120060785A (ko) 2012-06-12
EP2474533B1 (en) 2015-02-25
EP2474533A1 (en) 2012-07-11
WO2010135976A1 (zh) 2010-12-02
JP5722883B2 (ja) 2015-05-27
US8377932B2 (en) 2013-02-19
HK1166791A1 (en) 2012-11-09
DK2474533T3 (en) 2015-05-18
JP2012527488A (ja) 2012-11-08
EP2474533A4 (en) 2012-11-14
CN102149683B (zh) 2013-10-02
US20120129859A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
KR101478133B1 (ko) 1-（치환된 벤질기）-5-트리플루오로메틸-2-（1ｈ）피리돈 화합물 및 그 염의 제조방법 및 용도
JP5583758B2 (ja) １−（置換アリール）−５−トリフルオロメチル−２−（１ｈ）ピリドン化合物及びその塩、並びにその製造方法及びその用途
JP2004067629A (ja) ミトコンドリア機能活性化剤及び新規なベンゾイミダゾール誘導体
KR101264444B1 (ko) 록사핀 유사체 및 이것의 사용 방법
CN104829596B (zh) 吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途
CN105384739B (zh) 吡唑并[3,4-c]吡啶类衍生物
CA2841897A1 (en) Novel compound having parp inhibitory activity
Deng et al. Synthesis and discovery of new compounds bearing coumarin scaffold for the treatment of pulmonary fibrosis
IL170093A (en) Method for preparing acid addition salts of polyacidic basic compounds
CN114390924A (zh) 用于蛋白质降解的化合物、组合物和方法
CN119285617B (zh) 1,3,5-三取代吲哚衍生物及其应用
MXPA05002331A (es) Inhibidores de productos terminales de glicacion avanzada post-amadori.
HK1166791B (en) Preparation of 1-(substituted benzyl)-5-trifluoromethyl-2-(1h)pyridone compounds and salts thereof and their applications
HK1164297B (en) Preparation of 1-(substituted aryl)-5-trifluoromethyl-2-(1h)-pyridone compounds and salts thereof and their applications
CN121574094A (zh) 一种瑞巴派特伏诺拉生盐及其制备方法和应用
WO2014196784A1 (ko) 신규한 말레인산 유도체 및 이의 제조방법 및 이를 포함하는 항암용 조성물
WO2000055129A1 (en) Dithiocarbonimidate derivatives

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20171120

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20181219

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20221225

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20221225